Overview

• Hipra is investing €555 million in a 114,000 m² industrial and scientific complex in Aiguaviva, with the first phase due this autumn.
• The company’s 2024 revenue fell to €440.2 million from €452 million a year before, and net profit plunged 36% to €32.7 million as it reinvested in strategic projects.
• Last year’s R&D spend reached €62 million—14% of sales—with two-thirds dedicated to veterinary programs and 28 biological vaccines under development.
• Hipra launched Hipra Biotech Services late in 2024 with European Investment Bank backing and is handling two advanced industrial contracts for third parties.
• It plans to recruit 200 employees—almost half in scientific roles—after registering 3.5% growth in its animal health segment, twice the industry average.